skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.12d (Release date: 2017-12-26)
SearchBox Top
SearchBox Bottom
Inotuzumab Ozogamicin (Code C71542)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Inotuzumab Ozogamicin

Definition: A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.

Display Name: Inotuzumab Ozogamicin

Label: Inotuzumab Ozogamicin

NCI Thesaurus Code: C71542 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C1567130  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Inotuzumab Ozogamicin
Way 207294

External Source Codes: 
CAS Registry Number 635715-01-4 (see NLM ChemIDplus info)
PDQ Closed Trial Search ID 352004
PDQ Open Trial Search ID 352004 (check for NCI PDQ open clinical trial info)
UMLS CUI C1567130

Other Properties:
     Name Value (qualifiers indented underneath)
Accepted_Therapeutic_Use_For relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Chemical_Formula C73H96IN6O25S3
code C71542
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name Anti-CD22-CalichDMH_Conjugate
Semantic_Type Immunologic Factor
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom